search
Back to results

Exercise Training, Cognition, and Mobility in Older Adults With Multiple Sclerosis

Primary Purpose

Older Adults, Multiple Sclerosis, Cognitive Impairment

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Aerobic and Resistance Exercise Program (GEMS program)
Flexibility and Stretching Program (FLEX-MS program)
Sponsored by
University of Illinois at Chicago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Older Adults focused on measuring Cognition, Walking, Exercise, Physical Activity

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age 50 years or older Diagnosis of MS Relapse-free for the past 30 days Internet and e-mail access Ability to travel to the laboratory (for testing only) Willingness to complete the assessments and be randomized Ambulatory with or without a single-point assistive device Mild-to-moderate cognitive impairment (TICS-M; MSNQ) Walking impairment (MSWS-12) Exclusion Criteria: Individuals not meeting above inclusion criteria Individuals with moderate to high risk for contraindications of possible injury or death when undertaking strenuous or maximal exercise (PARQ) Individuals diagnosed with other neurological conditions or cardiovascular diseases

Sites / Locations

  • University of Illinois at ChicagoRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Aerobic and Resistance Exercise Program (GEMS program)

Flexibility and Stretching Program (FLEX-MS program)

Arm Description

This intervention condition will deliver the Guidelines for Exercise in Multiple Sclerosis (GEMS) program. Participants in this condition will receive a 16-week home-based, remotely supported aerobic and resistance exercise training intervention.

Participants in this condition will receive a 16-week home-based, remotely supported stretching program emphasizing flexibility and range of motion as important components of fitness based on Stretching for People with MS: An Illustrated Manual from the National MS Society.

Outcomes

Primary Outcome Measures

Cognitive Function
Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS); the total test scores range between 0 (min) and 236 (max), higher scores indicate better cognitive function.
Cognitive Function
National Institute of Health Toolbox (NIH toolbox) with customized cognitive test battery; the scores range between 0 (min) and 186 (max), higher scores indicate better cognitive function.
Physical Function
Short Physical Performance Battery (SPPB); the performance scores range between 0 (min) and 12 (max) points, higher scores reflect better physical function.
Lower-extremity Function
30-Second Sit to Stand Test (30STS). The score is the number of complete repetitions of sit-to-stand movements performed during 30 seconds; the minimum value is 0 repetitions, and the maximum value depends on individuals' performance. Higher scores reflect better lower extremity function.
Functional Mobility
Timed Up and Go Test (TUG); the score is the average time (in seconds) for completing two trials. The minimum and maximum scores depend on individuals' performance; shorter time (lower scores) reflects better functional mobility.
Walking Endurance
Six-Minute Walk Test (6MW); the score is the total walking distance (in meters) during the 6 minutes. The minimum value is 0 meter, and the maximum value depends on individuals' performance. A longer distance (higher scores) indicates better walking endurance.
Walking Speed
Timed 25-foot Walking Test (T25FW); the score is the average speed (25 feet divided by time, ft/s) for completing two trials. The minimum and maximum scores (time) depend on individuals' performance. A faster speed represents better ambulatory performance.

Secondary Outcome Measures

Physical Activity Level
Time spent in moderate-to-vigorous physical activity (MVPA) will be measured by a waist-worn accelerometer (ActiGraph model GT3X+); a longer time (in seconds) reflects a higher level of physical activity.
Physical Activity Level
Daily step count will be measured by a waist-worn accelerometer (ActiGraph model GT3X+); a greater number of steps per day reflects a higher level of physical activity.
Exercise Behavior
Godin Leisure-Time Exercise Questionnaire (GLTEQ); scores range between 0 (min) and 119 (max), higher scores indicate greater engagement in exercise behavior.
Vascular Function
Central blood pressure will be measured by waveform analysis using the SphygmoCor XCEL System. A higher value (in millimeters of mercury, or mmHg) indicate higher blood pressure.
Vascular Function
Augmentation index is a biomarker for arterial stiffness and will be measured using the SphygmoCor XCEL System. A higher value (percentage) indicates greater arterial stiffness.
Vascular Function
Carotid-to-femoral pulse wave velocity (cfPWV) is a biomarker for arterial stiffness and will be measured using the SphygmoCor XCEL System. A higher value (meters/second) indicates greater arterial stiffness.

Full Information

First Posted
June 7, 2023
Last Updated
July 5, 2023
Sponsor
University of Illinois at Chicago
search

1. Study Identification

Unique Protocol Identification Number
NCT05930821
Brief Title
Exercise Training, Cognition, and Mobility in Older Adults With Multiple Sclerosis
Official Title
Exercise Training, Cognition, and Mobility in Older Adults With Multiple Sclerosis
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 5, 2023 (Actual)
Primary Completion Date
May 1, 2024 (Anticipated)
Study Completion Date
May 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Illinois at Chicago

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The overall objective of the proposed randomized controlled (RCT) is to determine the feasibility and efficacy of a 16-week theory-based, remotely-delivered, combined exercise (aerobic and resistance) training intervention for improving cognitive and physical function in older adults (50+ years) with multiple sclerosis (MS) who have mild-to-moderate cognitive and walking impairment. Participants (N=50) will be randomly assigned into exercise training (combined aerobic and resistance exercise) condition or active control (flexibility and stretching) condition. The 16-week intervention will be delivered and monitored remotely within a participant's home/community and supported by Zoom-based chats guided by social cognitive theory (SCT) via a behavioral coach. Participants will receive training materials (e.g., prescriptive manual and exercise equipment), one-on-one coaching, action-planning via calendars, self-monitoring via logs, and SCT-based newsletters. It is hypothesized that the home-based exercise intervention will yield beneficial effects on cognition, mobility, physical activity, and vascular function compared with an active control condition (flexibility and stretching intervention), and these improvements will be sustained during a 16-week follow-up period.
Detailed Description
Multiple sclerosis (MS) is an immune-mediated and neurodegenerative disease of the central nervous system that is markedly increasing in prevalence amongst older adults. Older adults with MS present with poor health status and functioning, cognitive and ambulatory difficulty, dependence for activities of daily living, and reduced physical activity participation. The common approach for managing MS involves disease-modifying drugs, yet this first-line approach for medical management has little efficacy in older MS age groups (i.e., those 50+ years of age). Exercise training has been recognized as a promising approach for maintaining and/or restoring physical and cognitive health in older adults from the general population and younger adults with MS. To date, there is a dearth of research examining the benefits of exercise training among older adults with MS. The current study proposes a remotely-delivered exercise training program for improving cognition and mobility among older adults with MS. The proposed research adopts an innovative intervention approach (via telerehabilitation) with rigorous design for evaluating the feasibility and efficacy of a home-based exercise intervention program in older adults with MS who have cognitive and walking impairment. This exercise training program adopts an innovative intervention approach via telerehabilitation and is convenient and accessible for older adults with MS. This research may have practical relevance for improving physical activity among older adults with MS through alleviating travel concerns and reducing environmental/social barriers. If successful, the proposed project will provide foundations for implementing larger, high-quality RCTs using remotely-delivered exercise intervention for managing the consequences of aging and MS and ultimately contributing to successful aging with MS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Older Adults, Multiple Sclerosis, Cognitive Impairment, Walking Impairment
Keywords
Cognition, Walking, Exercise, Physical Activity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Aerobic and Resistance Exercise Program (GEMS program)
Arm Type
Experimental
Arm Description
This intervention condition will deliver the Guidelines for Exercise in Multiple Sclerosis (GEMS) program. Participants in this condition will receive a 16-week home-based, remotely supported aerobic and resistance exercise training intervention.
Arm Title
Flexibility and Stretching Program (FLEX-MS program)
Arm Type
Active Comparator
Arm Description
Participants in this condition will receive a 16-week home-based, remotely supported stretching program emphasizing flexibility and range of motion as important components of fitness based on Stretching for People with MS: An Illustrated Manual from the National MS Society.
Intervention Type
Behavioral
Intervention Name(s)
Aerobic and Resistance Exercise Program (GEMS program)
Intervention Description
Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on aerobic fitness and muscle strength as a mode of training. The exercise training prescription involves performing 3 days per week and include (a) aerobic exercise: 30+ minutes of moderate-intensity walking (≥100 steps/min) monitored by a waist-worn pedometer, and (b) resistance training: 1-2 sets, 10-15 repetitions of 5-10 exercises targeting lower and upper body, and core muscle groups using elastic bands. Other components of the GEMS program include appropriate exercise equipment (pedometer, resistance bands), one-on-one coaching sessions via Zoom, action-planning via calendars, logbooks for self-monitoring, and SCT-based newsletters.
Intervention Type
Behavioral
Intervention Name(s)
Flexibility and Stretching Program (FLEX-MS program)
Intervention Description
Remotely-coached/guided, home-based program delivered using telerehabilitation focusing on stretching and range of motion as the mode of training. The training will involve the same frequency, duration, timeline, behavior change content, and interactions with behavioral coach as the GEMS program, and account for activity, social-contact, and attention. Other components of the FLEX-MS program include appropriate exercise equipment (yoga mat), one-on-one coaching sessions via Zoom, calendars, logbooks and newsletters similar to the GEMS program.
Primary Outcome Measure Information:
Title
Cognitive Function
Description
Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS); the total test scores range between 0 (min) and 236 (max), higher scores indicate better cognitive function.
Time Frame
Changes in BICAMS test scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Cognitive Function
Description
National Institute of Health Toolbox (NIH toolbox) with customized cognitive test battery; the scores range between 0 (min) and 186 (max), higher scores indicate better cognitive function.
Time Frame
Changes in NIH toolbox cognitive test scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Physical Function
Description
Short Physical Performance Battery (SPPB); the performance scores range between 0 (min) and 12 (max) points, higher scores reflect better physical function.
Time Frame
Changes in physical function scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Lower-extremity Function
Description
30-Second Sit to Stand Test (30STS). The score is the number of complete repetitions of sit-to-stand movements performed during 30 seconds; the minimum value is 0 repetitions, and the maximum value depends on individuals' performance. Higher scores reflect better lower extremity function.
Time Frame
Changes in lower-extremity function scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Functional Mobility
Description
Timed Up and Go Test (TUG); the score is the average time (in seconds) for completing two trials. The minimum and maximum scores depend on individuals' performance; shorter time (lower scores) reflects better functional mobility.
Time Frame
Changes in functional mobility scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Walking Endurance
Description
Six-Minute Walk Test (6MW); the score is the total walking distance (in meters) during the 6 minutes. The minimum value is 0 meter, and the maximum value depends on individuals' performance. A longer distance (higher scores) indicates better walking endurance.
Time Frame
Changes in walking endurance scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Walking Speed
Description
Timed 25-foot Walking Test (T25FW); the score is the average speed (25 feet divided by time, ft/s) for completing two trials. The minimum and maximum scores (time) depend on individuals' performance. A faster speed represents better ambulatory performance.
Time Frame
Changes in walking speed scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Secondary Outcome Measure Information:
Title
Physical Activity Level
Description
Time spent in moderate-to-vigorous physical activity (MVPA) will be measured by a waist-worn accelerometer (ActiGraph model GT3X+); a longer time (in seconds) reflects a higher level of physical activity.
Time Frame
Changes in time spent in MVPA from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Physical Activity Level
Description
Daily step count will be measured by a waist-worn accelerometer (ActiGraph model GT3X+); a greater number of steps per day reflects a higher level of physical activity.
Time Frame
Changes in daily step count from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Exercise Behavior
Description
Godin Leisure-Time Exercise Questionnaire (GLTEQ); scores range between 0 (min) and 119 (max), higher scores indicate greater engagement in exercise behavior.
Time Frame
Changes in the GLTEQ scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Vascular Function
Description
Central blood pressure will be measured by waveform analysis using the SphygmoCor XCEL System. A higher value (in millimeters of mercury, or mmHg) indicate higher blood pressure.
Time Frame
Changes in central blood pressure from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Vascular Function
Description
Augmentation index is a biomarker for arterial stiffness and will be measured using the SphygmoCor XCEL System. A higher value (percentage) indicates greater arterial stiffness.
Time Frame
Changes in augmentation index from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Vascular Function
Description
Carotid-to-femoral pulse wave velocity (cfPWV) is a biomarker for arterial stiffness and will be measured using the SphygmoCor XCEL System. A higher value (meters/second) indicates greater arterial stiffness.
Time Frame
Changes in cfPWV from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Other Pre-specified Outcome Measures:
Title
Fatigue Severity
Description
Fatigue Severity Scale (FSS); scores range between 1 (min) and 7 (max), higher scores reflect greater fatigue severity.
Time Frame
Changes in fatigue severity scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Fatigue Impact
Description
Modified Fatigue Impact Scale (MFIS); scores range between 0 (min) and 84 (max), higher scores reflect a greater impact of fatigue on daily life.
Time Frame
Changes in fatigue impact scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Depressive Symptoms
Description
Hospital Anxiety and Depression Scale (HADS); scores range between 0 (min) and 21 (max), higher scores reflect greater frequency of anxiety and depressive symptoms.
Time Frame
Changes in depressive symptoms scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Anxiety
Description
Hospital Anxiety and Depression Scale (HADS); scores range between 0 (min) and 21 (max), higher scores reflect greater frequency of anxiety and depressive symptoms.
Time Frame
Changes in anxiety scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Level of Pain
Description
Short-form McGill Pain Questionnaire (SF-MPQ); scores range between 0 (min) and 45 (max), higher scores reflect higher level of pain.
Time Frame
Changes in pain level from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Sleep Quality
Description
Pittsburgh Sleep Quality Index (PSQI); scores range between 0 (min) and 21 (max), higher scores indicate worse sleep quality.
Time Frame
Changes in sleep quality scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Health-related Quality of Life
Description
Short Form Health Status Survey (SF-36); scores range between 0 (min) and 100 (max), higher scores indicate better physical and mental aspects of quality of life.
Time Frame
Changes in SF-36 scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)
Title
Health-related Quality of Life
Description
Multiple Sclerosis Impact Scale (MSIS-29); scores range between 0 (min) and 100 (max), higher scores indicate greater impact of disease on daily function (i.e. worse outcomes).
Time Frame
Changes in MSIS-29 scores from Baseline (pre-intervention), after 16 weeks (post-intervention), and after 32 weeks (follow-up)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 50 years or older Diagnosis of MS Relapse-free for the past 30 days Internet and e-mail access Ability to travel to the laboratory (for testing only) Willingness to complete the assessments and be randomized Ambulatory with or without a single-point assistive device Mild-to-moderate cognitive impairment (TICS-M; MSNQ) Walking impairment (MSWS-12) Exclusion Criteria: Individuals not meeting above inclusion criteria Individuals with moderate to high risk for contraindications of possible injury or death when undertaking strenuous or maximal exercise (PARQ) Individuals diagnosed with other neurological conditions or cardiovascular diseases
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Peixuan Zheng, Ph.D
Phone
312-996-4600
Email
pxzheng@uic.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peixuan Zheng, PhD
Organizational Affiliation
University of Illinois at Chicago
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Illinois at Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peixuan Zheng, PhD
Phone
312-355-0383
Email
pxzheng@uic.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Exercise Training, Cognition, and Mobility in Older Adults With Multiple Sclerosis

We'll reach out to this number within 24 hrs